Search
BIIB · Company research

Biogen Inc. Common Stock (BIIB): Stock News & Events

Recent company-linked news records available in the database.

Main stock researchCompare stocks
RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

32records availableHealthcare

Stock News & Events data

Database-backed records only

32 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowFour biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027. Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.View source ↗Zacks Investment ResearchOct 20, 2026bullish0.751
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 ResultsAbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market.View source ↗Zacks Investment ResearchOct 19, 2026bullish0.3331
BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use - StocktwitsBIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use StocktwitsView source ↗StocktwitsOct 14, 2026neutral00.6
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - StocktwitsBIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study StocktwitsView source ↗StocktwitsOct 14, 2026neutral00.6
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.View source ↗Zacks Investment ResearchOct 14, 2026bullish0.51
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options.View source ↗Zacks Investment ResearchOct 14, 2026bullish0.51
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.View source ↗Zacks Investment ResearchOct 13, 2026bullish0.3331
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios.View source ↗Zacks Investment ResearchOct 13, 2026bullish0.3331
Biogen (BIIB) Stock Is Up, What You Need To Know - Yahoo FinanceBiogen (BIIB) Stock Is Up, What You Need To Know Yahoo FinanceView source ↗Yahoo FinanceOct 12, 2026neutral00.6
Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom - Yahoo FinanceBiogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom Yahoo FinanceView source ↗Yahoo FinanceOct 12, 2026neutral00.6
Biogen Rises After Analyst Upgrade Highlights 2027 Pipeline Catalysts - Quiver QuantitativeBiogen Rises After Analyst Upgrade Highlights 2027 Pipeline Catalysts Quiver QuantitativeView source ↗Quiver QuantitativeOct 12, 2026neutral00.6
Biggest stock movers Monday: CCC, BIIB, ASTS, and more - Seeking AlphaBiggest stock movers Monday: CCC, BIIB, ASTS, and more Seeking AlphaView source ↗Seeking AlphaOct 12, 2026neutral00.6
Biogen (BIIB) Stock Is Up, What You Need To Know - The Globe and MailBiogen (BIIB) Stock Is Up, What You Need To Know The Globe and MailView source ↗The Globe and MailOct 12, 2026neutral00.6
BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300 - TradingViewBIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300 TradingViewView source ↗TradingViewOct 12, 2026neutral00.6
Biogen upgraded at JPMorgan with $300 PT on 2027 pipeline catalysts, shares rise (BIIB:NASDAQ) - Seeking AlphaBiogen upgraded at JPMorgan with $300 PT on 2027 pipeline catalysts, shares rise (BIIB:NASDAQ) Seeking AlphaView source ↗Seeking AlphaOct 12, 2026neutral00.6
Biogen (BIIB) Stock Forecast and Price Target 2026 $BIIB - MarketBeatBiogen (BIIB) Stock Forecast and Price Target 2026 $BIIB MarketBeatView source ↗MarketBeatOct 12, 2026neutral00.6
Biogen Inc (BIIB) Shares Surge 3.3% -- What GF Score of 73 Tells Investors - GuruFocusBiogen Inc (BIIB) Shares Surge 3.3% -- What GF Score of 73 Tells Investors GuruFocusView source ↗GuruFocusOct 9, 2026neutral00.6
How Positive Lupus Trial Data Will Impact Biogen Stock (BIIB) - Simply Wall StreetHow Positive Lupus Trial Data Will Impact Biogen Stock (BIIB) Simply Wall StreetView source ↗Simply Wall StreetOct 7, 2026neutral00.6
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Biogen Inc. (BIIB) has demonstrated a consistent pattern of beating earnings estimates, with an average surprise of 19.72% over the last two quarters. The company reported $3.6 per share versus an expected $3.04, and $3.57 versus expected $2.95 in the previous quarter. With a positive Earnings ESP of +2.19% and a Zacks Rank #3 (Hold), analysts suggest another earnings beat is likely when the company reports on October 28, 2026.View source ↗Zacks Investment ResearchOct 6, 2026bullish11
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Biogen Inc. (BIIB) has demonstrated a consistent pattern of beating earnings estimates, with an average surprise of 19.72% over the last two quarters. The company reported $3.6 per share versus an expected $3.04, and $3.57 versus expected $2.95 in the previous quarter. With a positive Earnings ESP of +2.19% and a Zacks Rank #3 (Hold), analysts suggest another earnings beat is likely when the company reports on October 28, 2026.View source ↗Zacks Investment ResearchOct 6, 2026bullish11
A Dravet medicine trial will measure changes in four areas of thinking and behavior - Stock TitanA Dravet medicine trial will measure changes in four areas of thinking and behavior Stock TitanView source ↗Stock TitanOct 5, 2026neutral00.6
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal - StocktwitsBIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal StocktwitsView source ↗StocktwitsOct 3, 2026neutral00.6
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year.View source ↗Zacks Investment ResearchOct 2, 2026bullish0.3331
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year.View source ↗Zacks Investment ResearchOct 2, 2026bullish0.3331
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - StocktwitsWhy Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? StocktwitsView source ↗StocktwitsSep 29, 2026neutral00.6
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - TradingViewWhy Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? TradingViewView source ↗TradingViewSep 28, 2026neutral00.6
3 Reasons to Sell BIIB and 1 Stock to Buy Instead - Yahoo Finance3 Reasons to Sell BIIB and 1 Stock to Buy Instead Yahoo FinanceView source ↗Yahoo FinanceAug 25, 2026neutral00.6
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating - ChartMillBiogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating ChartMillView source ↗ChartMillAug 17, 2026neutral00.6
BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.BIIB Stock Price Prediction 2026-2027 | Biogen Forecast 24/7 Wall St.View source ↗24/7 Wall St.Aug 14, 2026neutral00.6
Why Biogen (BIIB) Stock Is Up Today - Quiver QuantitativeWhy Biogen (BIIB) Stock Is Up Today Quiver QuantitativeView source ↗Quiver QuantitativeJul 29, 2026neutral00.6
Why Biogen (BIIB) Stock Is Up Today - Yahoo FinanceWhy Biogen (BIIB) Stock Is Up Today Yahoo FinanceView source ↗Yahoo FinanceJun 26, 2026neutral00.6
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD? - Yahoo FinanceShould You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD? Yahoo FinanceView source ↗Yahoo FinanceMay 29, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.